Steven Kanner Biography and Net Worth

Steve is the Chief Scientific Officer of Caribou Biosciences responsible for the company’s therapeutic discovery, research, and development activities. Before joining Caribou in 2017, Steve was Vice President, Head of Biology, at Arrowhead Pharmaceuticals, leading a department in discovery of RNAi therapeutics for oncology, genetic diseases, and other indications. Prior to Arrowhead Pharmaceuticals, he served in various positions of increasing responsibility in both oncology and inflammation drug discovery at Bristol-Myers Squibb, Agensys/Astellas, and Astex Pharmaceuticals. Steve has authored over 85 publications in both peer-reviewed journals and books, and he is an inventor on numerous U.S. and foreign patents and patent applications. Steve received his undergraduate degree in Genetics from the University of California, Berkeley and his Ph.D. in Immunology and Microbiology from the University of Miami’s Miller School of Medicine. His post-doctoral fellowship was funded by the National Institutes of Health and was conducted at the University of Virginia.

What is Steven Kanner's net worth?: The estimated net worth of Steven Kanner is at least $1.18 million as of August 25th, 2022. Dr. Kanner owns 302,059 shares of Caribou Biosciences stock worth more than $1,181,051 as of April 18th. This net worth approximation does not reflect any other investments that Dr. Kanner may own. Additionally, Dr. Kanner receives an annual salary of $500,510.00 as Insider at Caribou Biosciences. Learn More about Steven Kanner's net worth.
How old is Steven Kanner?: Dr. Kanner is currently 65 years old. There are 5 older executives and no younger executives at Caribou Biosciences. The oldest executive at Caribou Biosciences is Ms. Barbara G. McClung Esq., J.D., Chief Legal Officer & Corporate Secretary, who is 69 years old. Learn More on Steven Kanner's age.
What is Steven Kanner's salary?: As the Insider of Caribou Biosciences, Inc., Dr. Kanner earns $500,510.00 per year. There are 4 executives that earn more than Dr. Kanner. The highest earning executive at Caribou Biosciences is Dr. Rachel E. Haurwitz Ph.D., Co-Founder, CEO, President & Director, who commands a salary of $833,470.00 per year. Learn More on Steven Kanner's salary.
How do I contact Steven Kanner?: The corporate mailing address for Dr. Kanner and other Caribou Biosciences executives is , , . Caribou Biosciences can also be reached via phone at 510-982-6030 and via email at [email protected]. Learn More on Steven Kanner's contact information.
Has Steven Kanner been buying or selling shares of Caribou Biosciences?: Steven Kanner has not been actively trading shares of Caribou Biosciences within the last three months. Most recently, Steven Kanner sold 43,248 shares of the business's stock in a transaction on Thursday, August 25th. The shares were sold at an average price of $11.22, for a transaction totalling $485,242.56. Following the completion of the sale, the insider now directly owns 302,059 shares of the company's stock, valued at $3,389,101.98. Learn More on Steven Kanner's trading history.
Who are Caribou Biosciences' active insiders?: Caribou Biosciences' insider roster includes Ryan Fischesser (VP), Rachel Haurwitz (Co-Founder), Steven Kanner (Insider), and Barbara McClung (Insider). Learn More on Caribou Biosciences' active insiders.

Steven Kanner Insider Trading History at Caribou Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/25/2022	Sell	43,248	$11.22	$485,242.56	302,059
10/12/2021	Buy	114,860	$1.92	$220,531.20

Steven Kanner Buying and Selling Activity at Caribou Biosciences

Caribou Biosciences Company Overview

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Today's Range

Now: $3.91

$3.88

$4.02

50 Day Range

MA: $5.88

$3.91

$8.26

2 Week Range

Now: $3.91

$3.44

$8.59

Volume

1,415,632 shs

Average Volume

1,644,391 shs

Market Capitalization

$353.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.47

Biden’s $374B Giveaway Into This Sector

From DTI | Ad

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

Steven Kanner Biography and Net Worth

What is Steven Kanner's net worth?

How old is Steven Kanner?

What is Steven Kanner's salary?

How do I contact Steven Kanner?

Has Steven Kanner been buying or selling shares of Caribou Biosciences?

Who are Caribou Biosciences' active insiders?